Jerry L Ware

US Patent:

20080160024, Jul 3, 2008

Filed:

Dec 7, 2007

Appl. No.:

11/952198

Inventors:

Jerry Ware - Little Rock AR, US

Assignee:

BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS - Little Rock AR

International Classification:

A61K 39/395
A61K 38/00
A61K 35/00
A61P 43/00

US Classification:

4241351, 514 2, 4241301, 4241331, 424520

Abstract:

The present invention provides a method for inhibiting tumor cell metastasis in a subject. In particular, the method comprises administering a glycoprotein lbα inhibitor to the subject. The method may also be used for reducing tumor cell malignancy or inhibiting formation of a tumor cell embolism.

US Patent:

20110086030, Apr 14, 2011

Filed:

Dec 14, 2010

Appl. No.:

12/967272

Inventors:

Jerry Ware - Little Rock AR, US

Assignee:

BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS - Little Rock AR

International Classification:

A61K 39/395
A61P 35/00

US Classification:

4241351, 4241301, 4241411, 4241331

Abstract:

The present invention provides methods for inhibiting tumor cell metastasis. In particular, the invention provides methods for reducing tumor cell malignancy by administering to a subject an antibody that inhibits glycoprotein Ibα, such that tumor cell malignancy is reduced.

US Patent:

54279399, Jun 27, 1995

Filed:

Jan 6, 1992

Appl. No.:

7/817852

Inventors:

Zaverio M. Ruggeri - La Jolla CA
Jerry L. Ware - Encinitas CA

Assignee:

The Scripps Research Institute - La Jolla CA

International Classification:

C12N 121
C12N 510
C12N 1512
C12N 1563

US Classification:

4352402

Abstract:

A method of inhibiting platelet transfusion refractoriness comprising administering third-party platelets to a patient whose platelet glycoprotein Ib. alpha. polypeptides expressed from the patient's DNA have been determined to have either threonine or methionine residues, or both, at amino acid residue position 145 thereof, said third-party platelets having expressed at residue position 145 of the glycoprotein Ib. alpha. polypeptide thereof amino acids that are the same as those expressed on the glycoprotein Ib. alpha. polypeptides of the patient's platelets. Also, an antibody, or a fragment thereof, in substantially pure form having as its target epitope a domain of glycoprotein Ib. alpha. , the affinity of said antibody, or fragment thereof, for said epitope being dependent on the identity of the amino acid residue at position 145 of said glycoprotein. In addition, in a process for storing a supply of platelets for therapeutic use in a patient, the improvement comprising segregating said platelets into three stocks dependent upon whether residue 145 of glycoprotein Ib. alpha.

US Patent:

53407270, Aug 23, 1994

Filed:

Nov 14, 1990

Appl. No.:

7/613083

Inventors:

Zaverio M. Ruggeri - La Jolla CA
Jerry L. Ware - Encinitas CA

Assignee:

The Scripps Research Institute - La Jolla CA

International Classification:

C12N 1512
C12N 1585
A61K 3702

US Classification:

435 696

Abstract:

Recombinant DNA expression vectors encoding a peptide which inhibits binding of von Willebrand factor to platelet membrane glycoprotein Ib, said vector including a nucleotide sequence encoding the amino acid sequence from HIS. sup. 1 to LEU. sup. 610, inclusive, of the amino terminal region of platelet membrane glycoprotein Ib. alpha. , or any sequential subset thereof; mammalian host cells transformed by said vectors; and a process for producing a peptide having the identifying characteristics of the 45 kDa tryptic fragment of glycocalicin comprising the steps of (A) providing a stable, extrachromosomally replicable vector capable of directing in mammalian cells the expression of a nucleotide sequence encoding an amino acid sequence which includes said fragment, said nucleotide sequence further encoding as part of said amino acid sequence amino acids which are not native to said fragment, and which are oriented at the carboxy terminus of said fragment, (B) transforming said mammalian cells with said vector, and (C) maintaining said transformed mammalian cells under conditions permitting the expression of said peptide.

US Patent:

57982163, Aug 25, 1998

Filed:

Jun 6, 1995

Appl. No.:

8/470137

Inventors:

Zaverio M. Ruggeri - La Jolla CA
Jerry L. Ware - Encinitas CA

Assignee:

The Scripps Research Institute - La Jolla CA

International Classification:

G01N 33567
G01N 33537

US Classification:

435 721

Abstract:

A method of inhibiting platelet transfusion refractoriness comprising administering third-party platelets to a patient whose platelet glycoprotein Ib. alpha. polypeptides expressed from the patient's DNA have been determined to have either threonine or methionine residues, or both, at amino acid residue position 145 thereof, the third-party platelets having expressed at residue position 145 of the glycoprotein Ib. alpha. polypeptide thereof amino acids that are the same as those expressed on the glycoprotein Ib. alpha. polypeptides of the patient's platelets. Also, an antibody, or a fragment thereof, in substantially pure form having as its target epitope a domain of glycoprotein Ib. alpha. , the affinity of the antibody, or fragment thereof, for said epitope being dependent on the identity of the amino acid residue at position 145 of the glycoprotein. In addition, in a process for storing a supply of platelets for therapeutic use in a patient, the improvement comprising segregating the platelets into three stocks dependent upon whether residue 145 of glycoprotein Ib. alpha.

US Patent:

59004762, May 4, 1999

Filed:

Feb 26, 1992

Appl. No.:

7/841591

Inventors:

Zaverio M. Ruggeri - La Jolla CA
Jerry L. Ware - Encinitas CA

Assignee:

The Scripps Research Institute - La Jolla CA

International Classification:

C07K 14745
C12N 1512
A61K 3836

US Classification:

530380

Abstract:

A polypeptide which is capable of inhibiting binding of von Willebrand factor (vWF) to platelets and comprising an amino acid sequence that corresponds to the amino acid sequence of that fragment of mature von Willebrand factor subunit having its amino terminus at about Cys. sup. 509 and its carboxy terminus at about Cys. sup. 695, said polypeptide comprising optionally a second and/or a third domain, the second domain corresponding to the amino acid sequence of that fragment of mature vWF subunit having its amino terminus at about Thr. sup. 450 and its carboxy terminus at about Tyr. sup. 508, or a subfragment or combination of subfragments thereof, and a third domain corresponding to the amino acid sequence of that fragment of mature vWF subunit having its amino terminus at about Asp. sup. 696 and its carboxy terminus at about Gly. sup. 727, or a subfragment or combination of subfragments thereof; and also a process for producing said polypeptides from encoding DNA sequences, and also a method of inhibiting or treating thrombosis in a patient which comprising administering to such patient an effective amount of a therapeutic composition comprising one or more polypeptides of the invention.